Adenosine receptor PET imaging in human brain

International Review of Neurobiology

Volumn 119, Issue , 2014, Pages 51-69

  Mishina, Masahiro ^a,b   Ishiwata, Kiich ^b  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

Molecular imaging

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR; CARBON 2 (1 METHYL 4 PIPERIDINYL) 6 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL) 3(2H) PYRIDAZINONE C 11; CARBON 3,7 DIMETHYL 8 (3 IODOSTYRYL) 1 PROPARGYLXANTHINE C 11; CARBON 5 AMINO 7 [3 (4 METHOXYPHENYL)PROPYL] 2 (2 FURYL)PYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDINE C 11; CARBON 8 (3 BROMOSTYRYL) 3,7 DIMETHYL 1 PROPARGYLXANTHINE C 11; CARBON 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE C 11; CARBON 8 (3,4,5 TRIMETHOXYSTYRYL) 1,3,7 TRIMETHYLXANTHINE C 11; CARBON 8 DICYCLOPROPYLMETHYL 1 ETHYL 3 PROPYLXANTHINE C 11; CARBON 8 DICYCLOPROPYLMETHYL 1 METHYL 3 PROPYLXANTHINE C 11; FLUORINE 8 CYCLOPENTYL 3 (3 FLUOROPROPYL) 1 PROPYLXANTHINE F 18; FLUORODEOXYGLUCOSE F 18; IODINE 7 [2 [4 (2 FLUORO 4 IODOPHENYL)PIPERAZIN 1 YL]N 2 YL] 7H PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDIN 5 AMINE I 123; RADIOLIGAND; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BRAIN DAMAGE; DRUG STRUCTURE; HEMIANOPIA; HUMAN; ISOTOPE LABELING; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; SCHIZOPHRENIA; BRAIN; METABOLISM; SCINTISCANNING;

BRAIN; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, PURINERGIC P1;

EID: 84906768826     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801022-8.00002-7     Document Type: Chapter

References (84)

1. 1 adenosine receptors in human temporal lobe epilepsy: A quantitative autoradiographic study. Neuroscience Letters 1993, 163(1):11-14. 10.1016/0304-3940(93)90217-9.
2. 18F]CPFPX and positron emission tomography. NeuroImage 2003, 19(4):1760-1769. 10.1016/S1053-8119(03)00241-6.
3. Bauer A., Ishiwata K. Adenosine receptor ligands and PET imaging of the CNS. Handbook of Experimental Pharmacology 2009, 193:617-642. 10.1007/978-3-540-89615-9_19.
4. 18F]-MRS5425. Nuclear Medicine and Biology 2011, 38(6):897-906. 10.1016/j.nucmedbio.2011.01.009.
5. 1AR) in liver cirrhosis. European Journal of Nuclear Medicine and Molecular Imaging 2008, 35(3):589-597. 10.1007/s00259-007-0586-z.
6. 2A receptors in the brain. Synapse 2008, 62(9):671-681. 10.1002/syn.20539.
7. 2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004, 127:1075-1084. 10.1093/brain/awh128.
8. 1 receptors in dementia: Evidence for lack of specificity. Neuroscience Letters 1998, 244(1):1-4. 10.1016/S0304-3940(98)00108-6.
9. 2A receptors in schizophrenia. Neuroreport 2003, 14(3):313-316. 10.1097/01.wnr.0000058242.21747.04.
10. 1 adenosine receptor binding in the human brain: A positron emission tomography study. Journal of Neuroscience 2007, 27(9):2410-2415. 10.1523/JNEUROSCI.5066-06.2007.
11. Factor S., Mark M.H., Watts R., Struck L., Mori A., Ballerini R., et al. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism & Related Disorders 2010, 16(6):423-426. 10.1016/j.parkreldis.2010.02.014.
12. 1 receptors in the human brain: A quantitative autoradiographic study. Neuroscience 1987, 22(3):827-839. 10.1016/0306-4522(87)92962-9.
13. 1 receptors. Neuroreport 1994, 6(1):73-76.
14. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005, 366(9503):2112-2117. 10.1016/S0140-6736(05)67889-0.
15. Fredholm B.B., Svenningsson P. Adenosine-dopamine interactions: Development of a concept and some comments on therapeutic possibilities. Neurology 2003, 61(Suppl.):S5-S9. 10.1212/01.WNL.0000095204.89871.FF.
16. 11C]methyl-3-propylxanthine PET in Alzheimer's disease. Annals of Nuclear Medicine 2008, 22(10):841-847. 10.1007/s12149-008-0185-5.
17. 11C]MPDX. Annals of Nuclear Medicine 2003, 17(6):511-515. 10.1007/BF03006445.
18. 11C-methyl-3-propylxanthine. Journal of Nuclear Medicine 2005, 46(1):32-37.
19. A receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97(3):505-519. 10.1016/S0306-4522(00)00008-7.
20. 1 adenosine receptors in human temporal lobe epilepsy. Brain Research 1996, 710(1-2):56-68. 10.1016/0006-8993(95)01313-X.
21. 2A receptors in rats. Synapse 2001, 42(3):164-176. 10.1002/syn.1110.
22. 1 adenosine receptor antagonists as ligands for positron emission tomography (PET) and single-photon emission tomography (SPET). Journal of Medicinal Chemistry 1998, 41(4):555-563. 10.1021/jm9705465.
23. 1-adenosine receptor antagonist for in vivo imaging. Journal of Medicinal Chemistry 2002, 45(23):5150-5156. 10.1021/jm020905i.
24. 2A receptor mRNA expression in Parkinson's disease. Neuroscience Letters 2000, 291(1):54-58. 10.1016/S0304-3940(00)01371-9.
25. 1 and kappa 1 opioid receptors in the striatum in Alzheimer's disease. Brain Research 1993, 616(1-2):211-217. 10.1016/0006-8993(93)90211-5.
26. 2-like receptors in human striatum. Synapse 2009, 63(4):282-290. 10.1002/syn.20603.
27. Ishiwata K., Furuta R., Shimada J., Ishii S., Endo K., Suzuki F., et al. Synthesis and preliminary evaluation of [11C]KF15372, a selective adenosine A1 antagonist. Applied Radiation and Isotopes 1995, 46(10):1009-1013.
28. Ishiwata K., Kimura Y., de Vries E.F.J., Elsinga P.H. PET tracers for mapping adenosine receptors as probes for diagnosis of CNS disorders. Central Nervous System Agents in Medicinal Chemistry 2007, 7(1):57-77. 10.2174/187152407780059259.
29. Ishiwata K., Kimura Y., Oda K., Ishii K., Sakata M., Kawasaki K., et al. Development of PET radiopharmaceuticals and their clinical applications at the positron medical center. Geriatrics & Gerontology International 2010, 10(Suppl. 1):S180-S196. 10.1111/j.1447-0594.2010.00594.x.
30. 11C]TMSX. Synapse 2005, 55(2):133-136. 10.1002/syn.20099.
31. 1 receptors by positron emission tomography. Annals of Nuclear Medicine 2002, 16(6):377-382.
32. 2A antagonist. Applied Radiation and Isotopes 1996, 47(5-6):507-511. 10.1016/0969-8043(95)00295-2.
33. 2A receptor ligand. Journal of Nuclear Medicine 2000, 41(2):345-354.
34. 2A receptor in the central nervous system. Annals of Nuclear Medicine 2000, 14(4):247-253. 10.1007/BF02988206.
35. 2A receptors by positron emission tomography. Annals of Nuclear Medicine 2003, 17(3):205-211. 10.1007/BF02990023.
36. 1-receptors in the perforant pathway terminal zone in Alzheimer hippocampus. Neuroscience Letters 1991, 121(1-2):111-114. 10.1016/0304-3940(91)90661-C.
37. Jacobson K.A., Gao Z.G. Adenosine receptors as therapeutic targets. Nature Reviews. Drug Discovery 2006, 5(3):247-264. 10.1038/nrd1983.
38. Jansen K.L., Faull R.L., Dragunow M., Synek B.L. Alzheimer's disease: Changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors-An autoradiographic study. Neuroscience 1990, 39(3):613-627. 10.1016/0306-4522(90)90246-Z.
39. 1 receptors are decreased in Alzheimer's disease. Neuroscience Letters 1990, 118(2):257-260. 10.1016/0304-3940(90)90641-L.
40. 1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat. Psychopharmacology 2009, 201(4):529-539. 10.1007/s00213-008-1319-0.
41. 2A receptor antagonists as positron emission tomography (PET) tracers. Current Medicinal Chemistry 2013, 21(3):312-328.
42. 11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine. Nuclear Medicine and Biology 2004, 31(8):975-981. 10.1016/j.nucmedbio.2004.06.005.
43. 3H] CGS21680 binding in the striatum of postmortem brains of chronic schizophrenics. Brain Research 1998, 808(2):320-323. 10.1016/S0006-8993(98)00840-3.
44. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373(9680):2055-2066. 10.1016/S0140-6736(09)60492-X.
45. 3 adenosine receptor antagonists. Journal of Medicinal Chemistry 1999, 42(4):706-721. 10.1021/jm980550w.
46. Lohse M.J., Klotz K.N., Lindenborn-Fotinos J., Reddington M., Schwabe U., Olsson R.A. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)-A selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn-Schmiedeberg's Archives of Pharmacology 1987, 336(2):204-210. 10.1007/BF00165806.
47. 2A receptors in the limbic cortex, but not striatum, of aged rats. Journal of Neurochemistry 1999, 73(4):1733-1738. 10.1046/j.1471-4159.1999.731733.x.
48. 1 receptors. Journal of Pharmacological Sciences 2004, 96(1):42-52.
49. Magistretti P.J., Pellerin L. Cellular bases of brain energy metabolism and their relevance to functional brain imaging: Evidence for a prominent role of astrocytes. Cerebral Cortex 1996, 6(1):50-61. 10.1093/cercor/6.1.50.
50. 2 receptors: Selective localization in the human basal ganglia and alterations with disease. Neuroscience 1991, 42(3):697-706. 10.1016/0306-4522(91)90038-P.
51. 1 receptors in the brain. Nuclear Medicine and Biology 2005, 32(8):837-844. 10.1016/j.nucmedbio.2005.06.008.
52. 1 receptor binding in the rat brain: An autoradiographic study. Journal of Neuroscience Research 2004, 78(5):742-748. 10.1002/jnr.20314.
53. 18F]CPFPX PET study in humans. Neurobiology of Aging 2007, 28(12):1914-1924. 10.1016/j.neurobiolaging.2006.08.005.
54. 18F]CPFPX: Displacement studies in humans. NeuroImage 2006, 32(3):1100-1105. 10.1016/j.neuroimage.2006.04.202.
55. 11C]TMSX PET. Synapse 2007, 61(9):778-784. 10.1002/syn.20423.
56. 11C]TMSX PET in the striata of Parkinson's disease patients. PLoS One 2011, 6(2):e17338. 10.1371/journal.pone.0017338.
57. 2A receptors. Synapse 2012, 66(9):832-839. 10.1002/syn.21573.
58. Mizuno Y., Hasegawa K., Kondo T., Kuno S., Yamamoto M. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study. Movement Disorders 2010, 25(10):1437-1443. 10.1002/mds.23107.
59. 11C-MPDX as an indicator of severe cerebral ischemic insult. Journal of Nuclear Medicine 2003, 44(11):1839-1844.
60. 1 receptor ligand. Nuclear Medicine and Biology 1997, 24(1):53-59. 10.1016/S0969-8051(96)00161-8.
61. 2 receptor antagonist. European Journal of Pharmacology 1994, 267(3):335-341. 10.1016/0922-4106(94)90159-7.
62. 2 antagonist, (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. Journal of Medicinal Chemistry 1993, 36(23):3731-3733. 10.1021/jm00075a031.
63. 1 receptors in the central nervous system: Their functions in health and disease, and possible elucidation by PET imaging. Current Medicinal Chemistry 2011, 18(31):4820-4835.
64. Pellerin L., Magistretti P.J. Glutamate uptake into astrocytes stimulates aerobic glycolysis: A mechanism coupling neuronal activity to glucose utilization. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(22):10625-10629.
65. 2A selective adenosine receptor antagonist. British Journal of Pharmacology 1995, 115(6):1096-1102. 10.1111/j.1476-5381.1995.tb15923.x.
66. Rahman A. The role of adenosine in Alzheimer's disease. Current Neuropharmacology 2009, 7(3):207-216. 10.2174/157015909789152119.
67. Ramlackhansingh A.F., Bose S.K., Ahmed I., Turkheimer F.E., Pavese N., Brooks D.J. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011, 76(21):1811-1816. 10.1212/WNL.0b013e31821ccce4.
68. 2 antagonists. Journal of Medicinal Chemistry 1992, 35(12):2342-2345. 10.1021/jm00090a027.
69. 1 antagonist with renal protective and diuretic activities. Journal of Medicinal Chemistry 1991, 34(1):466-469. 10.1021/jm00105a072.
70. 1 adenosine receptor antagonist for SPECT. Nuclear Medicine and Biology 2003, 30(6):661-668. 10.1016/S0969-8051(03)00053-2.
71. 2A receptors. Nuclear Medicine and Biology 1997, 24(2):187-191. 10.1016/S0969-8051(96)00216-8.
72. 11C-8-dicyclopropylmethyl-1-methyl-3-propylxanthine. Clinical Nuclear Medicine 2012, 37(12):1146-1151. 10.1097/RLU.0b013e31826392a7.
73. 123I]MNI-420: A novel single photon emission computed tomography radiotracer for imaging of adenosine 2A receptors in brain. Nuclear Medicine and Biology 2013, 40(3):403-409. 10.1016/j.nucmedbio.2012.12.005.
74. 123I-MNI-420 in humans. Journal of Nuclear Medicine 2013, 54(10):1760-1767. 10.2967/jnumed.113.119933.
75. 2A receptor system using positron emission tomography. Journal of Medicinal Chemistry 2000, 43(23):4359-4362. 10.1021/jm0009843.
76. Tsacopoulos M., Magistretti P.J. Metabolic coupling between glia and neurons. Journal of Neuroscience 1996, 16(3):877-885.
77. 1 receptors to G proteins in Alzheimer hippocampus: A quantitative autoradiographic study. Neuroscience 1993, 52(4):843-854. 10.1016/0306-4522(93)90533-L.
78. 3 receptor. Nuclear Medicine and Biology 2008, 35(1):61-66. 10.1016/j.nucmedbio.2007.09.004.
79. 2A receptors with positron emission tomography. Nuclear Medicine and Biology 2000, 27(6):541-546. 10.1016/S0969-8051(00)00126-8.
80. Williams-Karnesky R.L., Stenzel-Poore M.P. Adenosine and stroke: Maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant. Current Neuropharmacology 2009, 7(3):217-227. 10.2174/157015909789152209.
81. 2A receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Brain Research 2011, 1367:310-318. 10.1016/j.brainres.2010.08.099.
82. 2A receptor signaling in the neostriatum. Neuroscience 2006, 141(1):19-25. 10.1016/j.neuroscience.2006.04.047.
83. 2A adenosine receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 1996, 276(2):398-404.
84. 2A adenosine receptor antagonist, to rat striatal membranes. British Journal of Pharmacology 1996, 117(7):1381-1386. 10.1111/j.1476-5381.1996.tb15296.x.